Literature DB >> 8202641

Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine.

B Rolinski1, I Sadri, J Bogner, F D Goebel.   

Abstract

Endothelin-1 (ET-1) is a potent vasoconstrictor peptide apparently involved in a number of vascular diseases in man. Nonetheless, its determination in biological samples is difficult, and data on plasma or urine concentrations are controversial. We investigated different sample preparation procedures as well as different radioimmunoassays for their influence on ET-1 measurement. Recovery of ET-1 depended on the extraction procedure, the type and size of the extraction columns and on the biological matrix itself. Incomplete removal of matrix components by the extraction leads to the formation of particulate matter in the evaporated eluate. When dissolved in assay buffer, ET-1 was found to be absorbed to and only partly released from these particulates, so that it was not accessible for measurement in a radioimmunoassay. This was the case for all extraction procedures investigated except for that involving acetic acid. HPLC analysis of spiked samples revealed that ET-1 is in part degraded during extraction, most probably to Meth-sulphoxide ET-1. Dilution curves of synthetic pure ET-1 standards from different suppliers, prepared either in plasma with subsequent extraction or in assay buffer of the respective radioimmunoassay, resulted in considerable differences in the measured values for ET-1-immunoreactivity. Every radioimmunoassay tested had a specific pattern of recognizing different synthetic ET-1 standards. In conclusion, the measurement of ET-1-immunoreactivity is strongly influenced by the experimental conditions of sample preparation as well as by the radioimmunoassay employed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8202641     DOI: 10.1007/bf02576362

Source DB:  PubMed          Journal:  Res Exp Med (Berl)        ISSN: 0300-9130


  7 in total

1.  Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial.

Authors:  D Tripathi; G Therapondos; J W Ferguson; D E Newby; D J Webb; P C Hayes
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

2.  Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide.

Authors:  A Helmy; D E Newby; R Jalan; P C Hayes; D J Webb
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

3.  Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.

Authors:  Neeraj Dhaun; Vanessa Melville; Scott Blackwell; Dinesh K Talwar; Neil R Johnston; Jane Goddard; David J Webb
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

4.  Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis.

Authors:  Neeraj Dhaun; Pajaree Lilitkarntakul; Iain M Macintyre; Eline Muilwijk; Neil R Johnston; David C Kluth; David J Webb; Jane Goddard
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-11

5.  Endothelin-1 immunoreactivity in plasma is elevated in HIV-1 infected patients with retinal microangiopathic syndrome.

Authors:  B Rolinski; S A Geier; I Sadri; V Klauss; J R Bogner; H Ehrenreich; F D Goebel
Journal:  Clin Investig       Date:  1994-03

6.  Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.

Authors:  D E Newby; N E Goodfield; A D Flapan; N A Boon; K A Fox; D J Webb
Journal:  Heart       Date:  1998-08       Impact factor: 5.994

7.  Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.

Authors:  Neeraj Dhaun; Jale Yuzugulen; Robert A Kimmitt; Elizabeth G Wood; Pajaree Chariyavilaskul; Iain M MacIntyre; Jane Goddard; David J Webb; Roger Corder
Journal:  J Am Heart Assoc       Date:  2015-03-23       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.